/JWCTF

JWCTF Stock - JW (Cayman) Therapeutics Co. Ltd

Q: What is the analyst price target for JWCTF?

Analyst price target information is not currently available for JWCTF.

Q: What is JWCTF's market cap?

Market capitalization information is not currently available for JWCTF.

Healthcare|Biotechnology|OTC

$0.39+7.53%

+$0.03 (+7.53%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.43

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for JWCTF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta2.03

52W High$0.66

52W Low$0.16

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$158.22M	$173.86M	$145.70M	$30.80M	N/A
Gross Profit	$77.32M	$88.22M	$58.76M	$9.04M	N/A
Gross Margin	48.9%	50.7%	40.3%	29.4%	N/A
Operating Income	$-459,281,000	$-789,607,000	$-855,883,000	$-759,083,000	$-440,838,000
Net Income	$-590,624,000	$-767,996,000	$-846,135,000	$-702,328,000	$-1,663,803,000
Net Margin	-373.3%	-441.7%	-580.7%	-2280.5%	N/A
EPS	$-1.43	$-1.87	$-2.06	$-1.76	$-12.61

Company Overview

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

Visit Website

Earnings History & Surprises

JWCTF

Beat Rate

25%

Last 8 quarters

Avg Surprise

-177.3%

EPS vs Estimate

Beats / Misses

2/6

Last 12 quarters

Latest EPS

$-0.12

Q4 2024

EPS Surprise History

Q2 22

+7.8%

$-0.16vs$-0.17

Q4 22

No data

Q1 23

-1.0%

$-0.15vs$-0.14

Q2 23

-9.0%

$-0.13vs$-0.12

Q4 23

No data

Q1 24

-16.0%

$-0.13vs$-0.11

Q3 24

+9.1%

$-0.08vs$-0.09

Q4 24

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 27, 2026	—	—	—	—
Q4 2024	Dec 31, 2024	—	$-0.12	—	—
Q3 2024	Aug 28, 2024	$-0.09	$-0.08	+9.1%	✓ BEAT
Q1 2024	Mar 20, 2024	$-0.11	$-0.13	-16.0%	✗ MISS
Q4 2023	Dec 31, 2023	—	$-0.13	—	—
Q2 2023	Jun 30, 2023	$-0.12	$-0.13	-9.0%	✗ MISS
Q1 2023	Mar 29, 2023	$-0.14	$-0.15	-1.0%	✗ MISS
Q4 2022	Dec 31, 2022	—	$-0.15	—	—
Q2 2022	Jun 30, 2022	$-0.17	$-0.16	+7.8%	✓ BEAT
Q1 2022	Mar 23, 2022	$-0.11	$-0.17	-56.7%	✗ MISS
Q4 2021	Dec 31, 2021	—	$-0.16	—	—
Q2 2021	Jun 30, 2021	$-0.11	$-0.11	-1.3%	✗ MISS
Q1 2021	Mar 26, 2021	$-0.08	$-1.18	-1351.0%	✗ MISS
Q4 2020	Dec 31, 2020	—	$-0.78	—	—
Q2 2020	Jun 30, 2020	—	$-0.32	—	—
Q4 2019	Dec 31, 2019	—	$-0.14	—	—
Q2 2019	Jun 30, 2019	—	$-0.18	—	—
Q1 2018	Jan 31, 2018	—	$-0.03	—	—

Frequently Asked Questions about JWCTF

What is JWCTF's current stock price?

JW (Cayman) Therapeutics Co. Ltd (JWCTF) is currently trading at $0.39 per share. The stock has moved +7.53% today.

What is the analyst price target for JWCTF?

No analyst price targets are currently available for this stock.

What sector is JW (Cayman) Therapeutics Co. Ltd in?

JW (Cayman) Therapeutics Co. Ltd operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.

What is JWCTF's market cap?

JW (Cayman) Therapeutics Co. Ltd has a market capitalization of $0.16 billion, making it a small-cap company.

Does JWCTF pay dividends?

No, JW (Cayman) Therapeutics Co. Ltd does not currently pay a dividend to shareholders.